Switch Bioworks partners with Bayer Crop Science on switchable nitrogen-fixing microbes
Bayer Crop Science backs Switch Bioworks' genetic switch for nitrogen fixation. Grow-room strains made five times more nitrogen than always-on controls.
Switch Bioworks announced a strategic collaboration with Bayer Crop Science on 13 October 2026, aimed at next-generation agricultural biologicals with biological nitrogen fixation as the first target. The company, headquartered in San Carlos, California, was founded in 2022 out of Stanford University and is led by founder and chief executive Dr Tim Schnabel. Neither party disclosed financial terms.
The technical idea is a timing fix. Microbes engineered to pump out nitrogen tend to lose the race for space on the root against the native soil microbiome, while microbes that colonise well tend not to fix enough nitrogen to matter to a grower. Switch builds its strains from the bottom up and installs a genetic switch: the microbe establishes itself first, then a change in the soil environment several weeks into the season turns on nitrogenase, the enzyme that converts nitrogen into ammonia. The trigger is undisclosed and needs no action from the farmer. In grow-room studies the switchable strains produced five times more nitrogen than always-on control strains, which the company attributes to better colonisation rather than a better enzyme. The switch technology sits behind seven patent families.
Bayer brings product development, formulation, field testing, commercialisation and crop genetics to the collaboration, and the first work combines Switch's best strains with a range of Bayer hybrids. Switch arrives with its regulatory position already built: the US Department of Agriculture and the Environmental Protection Agency have authorised first-in-class field releases, trials are running on corn at multiple sites across the US Midwest, and Brazil's National Technical Biosafety Commission, CTNBio, has approved the product. Schnabel has been clear that the 2026 trials are not statistically powered to measure fertiliser replacement or yield, so this season reads the switch rather than the business case.
On economics, the microbes are applied in-furrow at a small dose against synthetic nitrogen rates of 40 to 80 pounds per acre, roughly 45 to 90 kilograms per hectare, and Schnabel argues production cost sits far below the chemistry it would displace. "Farmers have paper thin margins, so even just $20 to $30 in savings per acre on fertilizer would be a huge deal," he said. He puts commercialisation two to three years out, a long-term target of replacing 25 per cent of synthetic nitrogen at maintained yields, and biology's ceiling at around 50 per cent, against a nitrogen fertiliser market the company sizes above $100 billion. Benoit Hartmann, who leads insights, innovation and partnerships at Bayer Crop Science, framed the deal around the company's product strategy, saying "Biologicals are another way we address these challenges". Schnabel called the partnership "a testament to the potential of our platform".
What this means for AgTech founders: the sequence here is the lesson. Switch did not sell a slide deck to a strategic, it sold a cleared regulatory path. USDA and EPA field-release authorisation plus a CTNBio approval are precisely the assets a corporate partner cannot buy quickly, and they are what turned a four-year-old company into a credible counterparty for a crop science division with its own biologicals pipeline and its own Ginkgo joint venture history. Note also what Switch did not try to build: germplasm, formulation, field trial networks and a route to the grower. Those are the four things that bankrupt biologicals startups one quarter at a time, and they are exactly what Bayer contributed. The caution is equally plain. Terms are undisclosed, no exclusivity is stated, and the field data that would prove fertiliser replacement does not exist yet, so what has been validated is the platform, not the product. Founders reading this as a template should take the order seriously: engineer a defensible mechanism, clear the regulators in more than one jurisdiction, and only then ask a corporate for the capabilities you were never going to fund yourself.
Switch Bioworks partners with Bayer Crop Science on switchable nitrogen-fixing microbes
The California company puts a genetic switch inside nitrogen-fixing microbes so they colonise the root first and start producing ammonia weeks later. Financial terms were not disclosed.
Switch Bioworks announced a strategic collaboration with Bayer Crop Science on 13 October 2026, aimed at next-generation agricultural biologicals with biological nitrogen fixation as the first target. The company, headquartered in San Carlos, California, was founded in 2022 out of Stanford University and is led by founder and chief executive Dr Tim Schnabel. Neither party disclosed financial terms.
The technical idea is a timing fix. Microbes engineered to pump out nitrogen tend to lose the race for space on the root against the native soil microbiome, while microbes that colonise well tend not to fix enough nitrogen to matter to a grower. Switch builds its strains from the bottom up and installs a genetic switch: the microbe establishes itself first, then a change in the soil environment several weeks into the season turns on nitrogenase, the enzyme that converts nitrogen into ammonia. The trigger is undisclosed and needs no action from the farmer. In grow-room studies the switchable strains produced five times more nitrogen than always-on control strains, which the company attributes to better colonisation rather than a better enzyme. The switch technology sits behind seven patent families.
Bayer brings product development, formulation, field testing, commercialisation and crop genetics to the collaboration, and the first work combines Switch's best strains with a range of Bayer hybrids. Switch arrives with its regulatory position already built: the US Department of Agriculture and the Environmental Protection Agency have authorised first-in-class field releases, trials are running on corn at multiple sites across the US Midwest, and Brazil's National Technical Biosafety Commission, CTNBio, has approved the product. Schnabel has been clear that the 2026 trials are not statistically powered to measure fertiliser replacement or yield, so this season reads the switch rather than the business case.
On economics, the microbes are applied in-furrow at a small dose against synthetic nitrogen rates of 40 to 80 pounds per acre, roughly 45 to 90 kilograms per hectare, and Schnabel argues production cost sits far below the chemistry it would displace. "Farmers have paper thin margins, so even just $20 to $30 in savings per acre on fertilizer would be a huge deal," he said. He puts commercialisation two to three years out, a long-term target of replacing 25 per cent of synthetic nitrogen at maintained yields, and biology's ceiling at around 50 per cent, against a nitrogen fertiliser market the company sizes above $100 billion. Benoit Hartmann, who leads insights, innovation and partnerships at Bayer Crop Science, framed the deal around the company's product strategy, saying "Biologicals are another way we address these challenges". Schnabel called the partnership "a testament to the potential of our platform".
What this means for AgTech founders: the sequence here is the lesson. Switch did not sell a slide deck to a strategic, it sold a cleared regulatory path. USDA and EPA field-release authorisation plus a CTNBio approval are precisely the assets a corporate partner cannot buy quickly, and they are what turned a four-year-old company into a credible counterparty for a crop science division with its own biologicals pipeline and its own Ginkgo joint venture history. Note also what Switch did not try to build: germplasm, formulation, field trial networks and a route to the grower. Those are the four things that bankrupt biologicals startups one quarter at a time, and they are exactly what Bayer contributed. The caution is equally plain. Terms are undisclosed, no exclusivity is stated, and the field data that would prove fertiliser replacement does not exist yet, so what has been validated is the platform, not the product. Founders reading this as a template should take the order seriously: engineer a defensible mechanism, clear the regulators in more than one jurisdiction, and only then ask a corporate for the capabilities you were never going to fund yourself.
